Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

INTRALIPIDS

PreclinicalSmall molecule

OOSF Healthcare System

INTRALIPIDS is one of 2 small molecule programs targeting Low Birth Weight. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Birth WeightCompleted

Low Birth WeightPreclinical

Completed

Competition

Competitive Landscape

1 competitor in Low Birth Weight

#DrugCompanyPhaseTrials

Verazinc

FFakultas Kedokteran Universitas Indonesia

INTRALIPIDS

OOSF Healthcare System

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Low Birth Weight1 trial

Tolerance of Increased Infusion Rates of Intravenous Fat Emulsions in Very Low Birth Weight Infants

Completed·OOSF Healthcare System·N/A·NCT00702767·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for INTRALIPIDS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INTRALIPIDS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INTRALIPIDS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OSF Healthcare System company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOSF Healthcare System

Related News